“Scratch One Flat Top” marked the sinking of an enemy aircraft carrier in the Battle of the Coral Sea.
In the battle over off-label promotion, scratch another lawsuit. Central Regional Employees Benefit Fund v. Cephalon, 2009 U.S. Dist. Lexis 93636 (D.N.J. Oct. 7, 2009), sends another would-be third party payor fraud suit to
A tip of the old cyberhat – and not for the first time – to Alan Modlinger at Lowenstein Sandler for passing along to us the latest good news on the off-label promotion front – dismissal (with leave to replead under Twombly) in In re Schering-Plough Corp. Intron/Temodar Consumer Class Action, slip op.
We’re not surprised that physicians invest in medical devices companies.
Legendary investor Peter Lynch said, “Buy what you know.” Surgeons who implant medical devices know . . . medical devices.
Sometimes those surgeons invent the devices. Sometimes the surgeons simply learn about the devices and believe they’re good products.
Not surprisingly, surgeons sometimes choose to
Having been in this business (defending pharmaceutical product liability) for a long time now, we’ve learned that what happens to prescribing doctors often comes back to haunt our clients. Nowhere is that better illustrated than with the thankfully discredited theory of regulatory informed consent, which since we’ve already discussed it, here, we won’t go
Judge Pratter’s recent decision in Wawrzynek v. Statprobe, Inc., No. 05-1342, 2007 WL 3146792 (E.D. Pa. Oct. 25, 2007), recently caught our eye. The decision raises a host of interesting questions.
First, how the heck do you pronounce that plaintiff’s name?
But wait, there’s more!
In a nutshell, Statprobe is a contract research organization that